S&P 500   5,041.43 (+0.38%)
DOW   37,950.27 (+0.52%)
QQQ   427.09 (+0.29%)
AAPL   167.73 (-0.16%)
MSFT   410.34 (-0.36%)
META   506.94 (+2.58%)
GOOGL   156.01 (+0.35%)
AMZN   181.52 (+0.13%)
TSLA   150.09 (-3.45%)
NVDA   855.63 (+1.82%)
AMD   155.85 (+1.19%)
NIO   4.03 (+3.07%)
BABA   69.29 (+0.68%)
T   16.20 (+0.50%)
F   12.10 (+0.50%)
MU   113.12 (-2.76%)
GE   156.58 (+0.58%)
CGC   7.67 (+18.18%)
DIS   113.43 (+0.43%)
AMC   2.90 (-2.68%)
PFE   25.32 (-0.39%)
PYPL   62.58 (-1.07%)
XOM   118.67 (+0.03%)
S&P 500   5,041.43 (+0.38%)
DOW   37,950.27 (+0.52%)
QQQ   427.09 (+0.29%)
AAPL   167.73 (-0.16%)
MSFT   410.34 (-0.36%)
META   506.94 (+2.58%)
GOOGL   156.01 (+0.35%)
AMZN   181.52 (+0.13%)
TSLA   150.09 (-3.45%)
NVDA   855.63 (+1.82%)
AMD   155.85 (+1.19%)
NIO   4.03 (+3.07%)
BABA   69.29 (+0.68%)
T   16.20 (+0.50%)
F   12.10 (+0.50%)
MU   113.12 (-2.76%)
GE   156.58 (+0.58%)
CGC   7.67 (+18.18%)
DIS   113.43 (+0.43%)
AMC   2.90 (-2.68%)
PFE   25.32 (-0.39%)
PYPL   62.58 (-1.07%)
XOM   118.67 (+0.03%)
S&P 500   5,041.43 (+0.38%)
DOW   37,950.27 (+0.52%)
QQQ   427.09 (+0.29%)
AAPL   167.73 (-0.16%)
MSFT   410.34 (-0.36%)
META   506.94 (+2.58%)
GOOGL   156.01 (+0.35%)
AMZN   181.52 (+0.13%)
TSLA   150.09 (-3.45%)
NVDA   855.63 (+1.82%)
AMD   155.85 (+1.19%)
NIO   4.03 (+3.07%)
BABA   69.29 (+0.68%)
T   16.20 (+0.50%)
F   12.10 (+0.50%)
MU   113.12 (-2.76%)
GE   156.58 (+0.58%)
CGC   7.67 (+18.18%)
DIS   113.43 (+0.43%)
AMC   2.90 (-2.68%)
PFE   25.32 (-0.39%)
PYPL   62.58 (-1.07%)
XOM   118.67 (+0.03%)
S&P 500   5,041.43 (+0.38%)
DOW   37,950.27 (+0.52%)
QQQ   427.09 (+0.29%)
AAPL   167.73 (-0.16%)
MSFT   410.34 (-0.36%)
META   506.94 (+2.58%)
GOOGL   156.01 (+0.35%)
AMZN   181.52 (+0.13%)
TSLA   150.09 (-3.45%)
NVDA   855.63 (+1.82%)
AMD   155.85 (+1.19%)
NIO   4.03 (+3.07%)
BABA   69.29 (+0.68%)
T   16.20 (+0.50%)
F   12.10 (+0.50%)
MU   113.12 (-2.76%)
GE   156.58 (+0.58%)
CGC   7.67 (+18.18%)
DIS   113.43 (+0.43%)
AMC   2.90 (-2.68%)
PFE   25.32 (-0.39%)
PYPL   62.58 (-1.07%)
XOM   118.67 (+0.03%)
OTCMKTS:IMLFF

InMed Pharmaceuticals (IMLFF) Stock Price, News & Analysis

$0.30
-0.01 (-3.23%)
(As of 04/17/2024 ET)
Today's Range
$0.26
$0.32
50-Day Range
$0.31
$0.44
52-Week Range
$3.04
$10.63
Volume
260,209 shs
Average Volume
11,369 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
IMLFF stock logo

About InMed Pharmaceuticals Stock (OTCMKTS:IMLFF)

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, it works on IND-enabling pharmacology and preclinical toxicology studies. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.

IMLFF Stock Price History

IMLFF Stock News Headlines

A.I. Pioneer Issues Urgent Warning to Americans
According to one early A.I. pioneer: “You can either use this as an unfair advantage to grow your wealth, or you can let it ravage your retirement savings. There’s no middle option.”
INM InMed Pharmaceuticals Inc.
InMed Provides Business Update and Milestones for 2023
A.I. Pioneer Issues Urgent Warning to Americans
According to one early A.I. pioneer: “You can either use this as an unfair advantage to grow your wealth, or you can let it ravage your retirement savings. There’s no middle option.”
What You Need To Know About CBD Hash
See More Headlines
Receive IMLFF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:IMLFF
CIK
N/A
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Eric A. Adams (Age 56)
    Pres, CEO & Director
  • Mr. Bruce S. Colwill C.A. (Age 55)
    CPA, CA, CFO & Corp. Sec.
  • Ms. Alexandra D. J. Mancini (Age 67)
    Sr. VP of Clinical & Regulatory Affairs
  • Dr. Eric Chih-Hsien Hsu (Age 50)
    Sr. VP of Preclinical R&D
  • Mr. Michael Woudenberg P.Eng. (Age 53)
    VP of Chemistry, Manufacturing & Controls
  • Dr. Sazzad Hossain
    Co-Founder
  • Mr. Brendan Payne
    Director of Investor Relations
  • Mr. Richard Hoy
    VP of Sales & Marketing
  • Dr. Ado Muhammad
    Sr. Consultant of Medical Affairs

IMLFF Stock Analysis - Frequently Asked Questions

How have IMLFF shares performed in 2024?

InMed Pharmaceuticals' stock was trading at $0.4160 on January 1st, 2024. Since then, IMLFF stock has decreased by 27.9% and is now trading at $0.30.
View the best growth stocks for 2024 here
.

How do I buy shares of InMed Pharmaceuticals?

Shares of IMLFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:IMLFF) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners